Testorelli C, Morelli S, Goldin A, Nicolin A
Br J Cancer. 1982 Mar;45(3):395-402. doi: 10.1038/bjc.1982.67.
A mouse of monoclonal cell line (L1) was produced by fusing the mouse myeloma P3X63/Ag8 with CD2F1 spleen cells immunized with a highly immunogenic subline of L1210 leukaemia (L1210/DTIC). A very few positive clones (1%) were isolated and one of these was chosen for detailed study. The monoclonal antibody L1 is an IgM immunoglobulin strongly reacting in a complement-dependent cytotoxicity assay against L1210/Cr leukaemia and its more or less immunogenic sublines. The specificity of the L1 antibody against L1210 leukaemia was studied by extensive screening with normal adult and foetal tissues, lymphoid tissues from several independent strains and a panel of the most common experimental tumours, to all of which it was unreactive. Attempts at immunotherapy were carried out in DBA/2 mice challenged with L1210 leukaemia and treated with L1 (ascites) and complement. Although the in vitro cytotoxic titre of ascites fluid from mice bearing hybridoma was very high (10(-7)), no therapeutic effect was obtained in vivo.
通过将小鼠骨髓瘤P3X63/Ag8与用高免疫原性的L1210白血病亚系（L1210/DTIC）免疫的CD2F1脾细胞融合，制备了单克隆细胞系（L1）的小鼠。分离出极少量的阳性克隆（1%），并选择其中一个进行详细研究。单克隆抗体L1是一种IgM免疫球蛋白，在针对L1210/Cr白血病及其或多或少具有免疫原性的亚系的补体依赖性细胞毒性试验中强烈反应。通过用正常成年和胎儿组织、来自几个独立品系的淋巴组织以及一组最常见的实验性肿瘤进行广泛筛选，研究了L1抗体对L1210白血病的特异性，结果发现该抗体对所有这些组织均无反应。在用L1210白血病攻击并用L1（腹水）和补体治疗的DBA/2小鼠中进行了免疫治疗尝试。尽管携带杂交瘤的小鼠腹水中的体外细胞毒性滴度非常高（10^(-7)），但在体内未获得治疗效果。
